Friday, 6 November 2026European Markets

SCATEC And ELEC.STRASBOURG Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(vianews) - scatec (scatc.ol) is among this list of stock assets with the highest dividend rate and return on equity on the utilities sector.

financial asset price forward dividend yield return on equity
scatec (scatc.ol) kr59.50 3.46% 2.17%
elec.strasbourg (elec.pa) €91.20 2.81% 13.75%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. scatec (scatc.ol)

3.46% forward dividend yield and 2.17% return on equity

scatec asa, together with its subsidiaries, provides renewable energy solutions worldwide. the company operates through power production; services; and development & construction segments. it develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. the company is also involved in the engineering, procurement, construction, operation, maintenance, and asset management of power plants. it has a total of 4.6 gw in operation and under construction. the company was formerly known as scatec solar asa and changed its name to scatec asa in november 2020. scatec asa was incorporated in 2007 and is headquartered in oslo, norway.

earnings per share

as for profitability, scatec has a trailing twelve months eps of kr0.21.

pe ratio

scatec has a trailing twelve months price to earnings ratio of 283.33. meaning, the purchaser of the share is investing kr283.33 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.17%.

volatility

scatec's last week, last month's, and last quarter's current intraday variation average was a positive 1.88%, a negative 0.62%, and a positive 1.82%.

scatec's highest amplitude of average volatility was 2.13% (last week), 2.84% (last month), and 1.82% (last quarter).

revenue growth

year-on-year quarterly revenue growth grew by 17.8%, now sitting on 3.25b for the twelve trailing months.

more news about scatec.

2. elec.strasbourg (elec.pa)

2.81% forward dividend yield and 13.75% return on equity

électricite de strasbourg société anonyme engages in the supply of electricity and natural gas to individuals, businesses, and local authorities in france. it is also involved in the design, construction, and operation of electrical engineering, industrial, and public lighting facilities, as well as heating networks; provision of collective catering engineering and energy renovation services; and technical management and optimization of energy installations. the company was founded in 1899 and is based in strasbourg, france. électricite de strasbourg société anonyme is a subsidiary of edf développement environnement sa.

earnings per share

as for profitability, elec.strasbourg has a trailing twelve months eps of €5.44.

pe ratio

elec.strasbourg has a trailing twelve months price to earnings ratio of 16.76. meaning, the purchaser of the share is investing €16.76 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.75%.

more news about elec.strasbourg.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com